Short-term effect of Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, on patients with rheumatic mitral regurgitation and preserved left ventricular systolic function.

Farrag, Hazem Mohammed; Fahim, Ragab Ismail; Abdelkader Abdelwahab, Mohamed

doi:10.21608/mjmr.2024.295355.1721

	Short-term effect of Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, on patients with rheumatic mitral regurgitation and preserved left ventricular systolic function.
Minia Journal of Medical Research
Articles in Press, Accepted Manuscript, Available Online from 01 July 2024
Document Type: Original Article
DOI: 10.21608/mjmr.2024.295355.1721
View on SCiNiTO
Authors
Hazem Mohammed Farrag¹; Ragab Ismail Fahim ²; Mohamed Abdelkader Abdelwahab³
¹Department of Cardiology, Faculty of Medicine, Minia University, Minia, Egypt
²Cardiology department, Faculty of medicine, Minia university, Minia City, Egypt
³cardiology ,faculty of medicine , minia university . Minia
Abstract
Background: SGLT2 inhibitors have been demonstrated to lower cardiovascular mortality risk and HF worsening in patients of HF with reduced, mildly reduced and preserved ejection fraction regardless of diabetes status (1) However, its effect on patients with mitral regurgitation and preserved LV systolic function is unclear (2). Aims: Study the short-term effects of Dapagliflozin on functional capacity, symptoms and LV systolic function in patient with rheumatic mitral regurgitation and preserved LV systolic function. Patients and Methods: A prospective cohort study, that included 150 patients with severe rheumatic mitral regurgitation and preserved left ventricular function (LV EF > 60%), 75 patients received dapagliflozin and 75 patients did not receive dapagliflozin served as a control group were studied and followed up after 3-month using 2D speckle tracking echocardiography and the Kansas City Cardiomyopathy Questionnaire (KCCQ). Results: After three months of follow-up, there was significant improvement in KCCQ score in patients who received dapagliflozin compared to those who didn’t, (p value< 0.001) However, no statistically significant difference in GLS between cases and control regarding basal GLS and GLS. Conclusions: Dapagliflozin relieves symptoms in patients with severe rheumatic mitral regurgitation and preserved LV function during a short-term follow-up in spite that no improvement in LV systolic function.
Keywords
Dapagliflozin; rheumatic mitral regurgitation; speckle tracking; KCCQ


Statistics Article View: 162